Abd El Salam Hayam A, Abdelglil Mostafa I, Sabry Eman, Abdelraof Mohamed, Abdelwahed Sameh, Gadallah Mona A, El-Rashedy Ahmed A, Saleh Asmaa, Srour Aladdin M
Green Chemistry Department, Chemical Industries Research Institute, National Research Centre, Dokki, Giza 12622, Egypt.
Al-Farahidi University- Baghdad, Iraq.
Bioorg Chem. 2025 Aug;163:108627. doi: 10.1016/j.bioorg.2025.108627. Epub 2025 May 25.
A new series of Benzimidazole pyridinecarbonitrile scaffolds 4a-r have been designed and synthesized through a regioselective Michael addition interaction between 2-acetyl N-propyne-benzimidazole (1) and ylidenemalononitrile (2), facilitated by a freshly prepared sodium methoxide solution. All synthesized derivatives were assessed for their antimicrobial potential on S. aureus (Gram-positive), P. aeruginosa (Gram-negative), as well as C.albicans (unicellular fungal). Derivatives 4a, 4c, 4f, 4l, 4m and 4q showed promising antimicrobial properties against all the tested MDR pathogens. In particular, compounds 4c, 4f, 4l, and 4m demonstrated brilliant inhibitory activity on C.albicans with MIC = 10 μg/mL each, a 4-fold increase compared to Amphotericin B (MIC = 40 μg/mL). While compound 4a presented MIC = 10 μg/mL compared with ciprofloxacin (MIC = 20 μg/mL) against MRSA, the MIC recorded by 4c and 4f against P. aeruginosa was 20 μg/mL, which equals that of ciprofloxacin. Bacterial lipid peroxidation (LPO) and antibiofilm activity and evaluation of reactive oxygen species (ROS) induced by the most potent derivatives were evaluated, revealing that derivatives 4f and 4m demonstrated the best behavior among the tested compounds. Furthermore, molecular docking and molecular dynamics (MD) simulations validated the stability of compound 4f within the catalytic binding pocket of the DNA gyrase receptor. The molecules were geometrically optimized using DFT with the B3LYP 6-21 basis set, and their electronic properties were analyzed. The study also encompassed ADME predictions and drug-likeness assessments for the new compounds.
通过新制备的甲醇钠溶液促进,2-乙酰基-N-丙炔基苯并咪唑(1)与亚甲基丙二腈(2)之间的区域选择性迈克尔加成相互作用,设计并合成了一系列新的苯并咪唑吡啶甲腈支架4a-r。对所有合成衍生物针对金黄色葡萄球菌(革兰氏阳性)、铜绿假单胞菌(革兰氏阴性)以及白色念珠菌(单细胞真菌)的抗菌潜力进行了评估。衍生物4a、4c、4f、4l、4m和4q对所有测试的多重耐药病原体均显示出有前景的抗菌性能。特别是,化合物4c、4f、4l和4m对白色念珠菌表现出出色的抑制活性,MIC均为10μg/mL,与两性霉素B(MIC = 40μg/mL)相比增加了4倍。与环丙沙星(MIC = 20μg/mL)针对耐甲氧西林金黄色葡萄球菌相比,化合物4a的MIC为10μg/mL,而4c和4f针对铜绿假单胞菌的MIC为20μg/mL,与环丙沙星相当。评估了最具活性的衍生物诱导的细菌脂质过氧化(LPO)、抗生物膜活性以及活性氧(ROS),结果表明衍生物4f和4m在测试化合物中表现最佳。此外,分子对接和分子动力学(MD)模拟验证了化合物4f在DNA促旋酶受体催化结合口袋内的稳定性。使用B3LYP 6-21基组通过密度泛函理论(DFT)对分子进行几何优化,并分析了它们的电子性质。该研究还包括对新化合物的吸收、分布、代谢和排泄(ADME)预测以及类药性评估。